Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics (ticker: INKT) and First Lviv Territorial Medical Union have started a randomized Phase 2 trial of agenT-797, an off-the-shelf allogeneic iNKT cell therapy, in severe acute lung injury (ALI) and hypoxemic respiratory failure.
The placebo-controlled C-1300-02 study, authorized by Ukraine’s Ministry of Health and supported by an active U.S. IND, will assess survival, ventilator-free days, ICU recovery, pathogen control, and secondary infections. Expansion to U.S. sites is underway, with preliminary data expected in the second half of 2026.
MiNK Therapeutics (NASDAQ: INKT) reported ASGCT 2026 data on its off-the-shelf iNKT therapy agenT-797, showing context-dependent immune responses from the same donor batch without genetic engineering.
In 34 solid tumor patients it induced TH1 IFN-gamma elevation; in 20 ARDS patients it induced TH2 IL-4/IL-13 elevation, with associated clinical responses and a favorable safety profile, supporting advancement to a randomized Phase 2 acute lung injury trial with preliminary data expected in 2026.
Agenus (Nasdaq: AGEN) reported Q1 2026 results and key BOT+BAL milestones. Total revenue was $33.7M (vs $24.1M Q1 2025), with net income of $39.2M (vs $(26.4)M loss). Cash was $35.0M at March 31, 2026.
BOT+BAL advanced into Phase 3 BATTMAN enrollment, authorized access expanded globally, and the $91M Zydus collaboration closed, adding capital and U.S. manufacturing capacity. The SEC investigation concluded with no enforcement action, and a related securities class action was dismissed.
MiNK Therapeutics (NASDAQ: INKT) will report first quarter 2026 financial results for the period ended March 31, 2026, before market open on May 15, 2026. A conference call and webcast will be held at 8:30 AM ET to review results and provide a corporate update.
The update will cover progress across the iNKT cell therapy platform, including clinical development, translational research, platform expansion, strategic initiatives, continued advancement of lead allo-iNKT therapy agenT-797, recent scientific presentations, and a collaboration with C-Further on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. A live webcast and replay will be available on the company website.
MiNK Therapeutics (NASDAQ: INKT) reported Phase II data (n=17) of agenT-797 with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer, presented at AACR April 17–22, 2026. The regimen produced a 77% disease control rate, induction-associated median PFS 6.9 vs 3.5 months (HR 0.19; p=0.015), and longer median OS (9.5 vs 5.2 months) with 43% of induction patients alive at 12 and 18 months. Correlatives showed intratumoral T cell and dendritic cell infiltration and tertiary lymphoid structure formation. The study did not meet its primary ORR endpoint; safety was consistent with component agents.
MiNK Therapeutics (NASDAQ: INKT) will present Phase II data for agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer at AACR 2026.
The investigator-initiated trial at Memorial Sloan Kettering evaluates immune reprogramming and treatment sequencing in checkpoint-refractory GEC; presentation is April 20, 2026, Poster Section 52, Abstract CT166.
MiNK Therapeutics (NASDAQ: INKT) announced that an abstract on its investigational allogeneic iNKT cell therapy agenT-797 was accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 11-15, 2026, in Boston.
Presenter Terese C. Hammond, MD, will present data titled "AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS." Session timing and poster location will be posted on the ASGCT conference program website in mid-April.
MiNK Therapeutics (NASDAQ: INKT) announced an abstract acceptance for presentation at the American Thoracic Society (ATS) 2026 International Conference in Orlando, May 15-20, 2026. The abstract describes a combination of N-803 and investigational agenT-797 for unresolving Coccidioides immitis infection.
Presenter Terese Hammond, MD, will present Poster Board #103 in Session D107 on Wednesday, May 20, 2026, 11:00 AM–1:00 PM EDT. In line with ATS rules, no data or results are disclosed until the conference presentation.
MiNK Therapeutics (NASDAQ: INKT) reported Q4 and full‑year 2025 results and highlighted multiple 2026 clinical catalysts. Key facts: cash $13.4M at year‑end, an additional $3.0M raised post‑year, net loss $12.5M for FY2025, and advancing Phase 2 ARDS and GVHD programs with near‑term readouts.
Non‑dilutive funding includes a $1.1M C‑Further collaboration, an NIH NIAID STTR grant, and the Mary Gooze award, supporting clinical starts in 1H–2H 2026.
MiNK Therapeutics (NASDAQ: INKT) will report fourth quarter and full year 2025 financial results before market open on March 31, 2026 and host a conference call and webcast at 8:30 a.m. ET.
The company also highlighted platform expansion with a collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers, citing non-dilutive funding and downstream commercial revenue potential.